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Aldosterone plays an important role in the pathophysiology of heart failure.
Aldosterone receptor blockade has been shown to reduce morbidity and
mortality in human patients with advanced congestive left ventricular heart
failure. This study was designed to assess the efficacy and tolerance of long-term
low-dose spironolactone when added to conventional heart failure treatment in
dogs with advanced heart failure. Eighteen client-owned dogs with advanced
congestive heart failure due to either degenerative valve disease (n = 11) or
dilated cardiomyopathy (n = 7) were included in this prospective, placebo-
controlled, double-blinded, randomized clinical study. After initial stabilization
including furosemide, angiotensin-converting enzyme inhibitors, pimobendan
and digoxin, spironolactone at a median dose of 0.52 mg ⁄ kg (range
0.49–0.8 mg ⁄ kg) once daily (n = 9) or placebo (n = 9) was added to the
treatment, and the dogs were reassessed 3 and 6 months later. Clinical scoring,
echocardiography, electrocardiogram, systolic blood pressure measurement,
thoracic radiography, sodium, potassium, urea, creatinine, alanine amino-
transferase, aldosterone and aminoterminal atrial natriuretic propeptide were
assessed at baseline, 3 and 6 months. Survival times were not significantly
different between the two treatment groups. Spironolactone was well tolerated
when combined with conventional heart failure treatment.
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INTRODUCTION
In humans and animals with advanced congestive heart failure,
serum aldosterone concentrations are increased as a result of the
activation of the renin–angiotensin–aldosterone system (RAAS)
(Swedberg et al., 1990). Aldosterone plays a key role in the
pathophysiology of congestive heart failure. It promotes the
retention of sodium, the loss of magnesium and potassium,
sympathetic activation, parasympathetic inhibition, myocardial
and vascular remodelling, baroceptor dysfunction and impairs
arterial compliance (Struthers, 2004). The actions of aldoste-
rone, although beneficial in the short term, contribute to the
progression of heart failure in the long term (Katz, 2003).
Treatment with angiotensin conversion enzyme (ACE) inhibitors
reduces angiotensin II and aldosterone production and has been
shown to be of great clinical benefit in the treatment of heart
failure in humans (CONSENSUS study, 1987) and dogs (COVE
study, 1995; IMPROVE study, 1995; Ettinger et al., 1998;
BENCH study, 1999). However, in up to 45% of human patients
with heart failure, serum aldosterone and ⁄ or angiotensin II
concentrations are elevated despite treatment with ACE inhib-
itors, a phenomenon called ‘aldosterone escape’ (MacFadyen
et al., 1999; Van de Wal et al., 2006). Treatment with ACE
inhibitors may therefore not be sufficient to control aldosterone
production, and concurrent aldosterone receptor blockade may
be beneficial. The ‘Randomised Aldactone Evaluation Study’
(RALES), a large, multicentre study involving 1663 human
patients, showed that spironolactone, when added in a low dose
(25 mg ⁄ day), which will not lead to significant diuresis, to
conventional treatment with ACE inhibitors, diuretics and
cardiac glycosides, significantly reduces morbidity and mortality
in human patients with advanced left ventricular dysfunction
(Pitt et al., 1999). The beneficial effect of spironolactone on
survival was most pronounced in patients with elevated serum
concentrations of procollagen III aminoterminal peptide
(PIIINP), a serum marker of increased extracellular matrix
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turnover. It was suggested that spironolactone acts by blunting
aldosterone-induced myocardial remodelling, in particular myo-
cardial fibrosis (Zannad et al., 2000). Further subgroup studies
showed a significant decrease in plasma brain natriuretic peptide
(BNP) and N-terminal peptide of the aminoterminal atrial
natriuretic propeptide (NT-proANP) as well as a significant
increase in plasma angiotensin II and aldosterone in patients
treated with low-dose spironolactone, indicating that, at this dose,
spironolactone induced significant neurohormonal changes that
could be responsible for the beneficial effect on morbidity and
mortality (Rousseau et al., 2002).
However, combined treatment with ACE inhibitors and
spironolactone has been a concern in humans, especially for
patients with reduced renal function, given that both drugs work
synergistically via reduction in aldosterone secretion (ACE
inhibitors) and inhibition of aldosterone binding to its receptor
(spironolactone) and thus can lead to life-threatening hyperkal-
aemia (Berry & McMurray, 2001; Juurlink et al., 2004).
A recent clinical trial showed a significant decrease in
mortality in dogs with moderate to severe mitral valve disease
when spironolactone was added at 2 mg ⁄ kg once daily (Bernay
et al., 2010). Concurrent treatment with an ACE inhibitor and
spironolactone was well tolerated in that study.
The aims of the present randomized, prospective, double-
blinded, placebo-controlled clinical study were firstly to assess
the efficacy of long-term treatment with a low dose of
spironolactone in addition to conventional treatment including
furosemide, ACE inhibitors, pimobendan and digoxin on survival
and on clinical, biochemical and neuroendocrine parameters in
dogs with advanced heart failure due to either degenerative
valve disease (DVD) or dilated cardiomyopathy (DCM) and
secondly to evaluate its tolerance in this category of patients. The
dose of spironolactone used in this trial (0.5–0.8 mg ⁄ kg once
daily) was chosen to be clearly below the approved diuretic dose
in dogs (2–4 mg ⁄ kg once daily) to show that potential positive
effects of spironolactone are due to other than diuretic effects.
MATERIAL AND METHODS
The study was designed as a prospective, randomized, double-
blined placebo-controlled clinical trial. It was performed at the
Department of Small Animal Clinical Studies of the Faculty of
Veterinary Medicine, University of Lie`ge (Belgium). The study
protocol was approved by the ethics committee for animal
research of the University of Lie`ge (Belgium). Informed consent
was obtained from each owner before enrolment of the animal in
the study protocol.
Animals
Eighteen client-owned dogs of various breeds were included.
Inclusion criteria were presence of advanced heart failure
[Classes II and III according to the Scandinavian modified New
York Heart Association system (NYHA); Table 1] secondary to
either DVD or DCM, absence of severe concurrent disease and
clinically stable heart disease for a minimum of 4 weeks on
conventional treatment. Accepted conventional treatments were
furosemide, ACE inhibitors (benazepril or enalapril), pimobendan
and digoxin. Exclusion criteria were uncontrolled congestive
heart failure despite conventional treatment, severe concurrent
extra-cardiac disease and need for spironolactone at diuretic dose
(2–4 mg ⁄ kg ⁄ day). Initial diagnosis and staging were based on
history, clinical findings, electrocardiogram (ECG), thoracic
radiography and echocardiography. Haematology and serum
biochemistry (not shown) were performed in all patients as part
of the initial work up.
Treatment groups
The dogs were paired in order of admission to the study and
assigned in either of two treatment groups: Group 1 received
spironolactone at a median dose of 0.52 mg ⁄ kg once daily
(range 0.5–0.8 mg ⁄ kg); Group 2 received a placebo (vehicle
tablets) in addition to conventional treatment. Spironolactone
(2 mg) and placebo tablets were both prepared by the Depart-
ment of Pharmacology of the Centre Hospitalier Universitaire of
the University of Lie`ge and were identical in appearance. The
tablets were administered per mouth with food. The study was
double-blinded, with the investigators and the owners unaware
of treatment group assignment of individual dogs.
Clinical evaluation
The dogs included in the study were scheduled for evaluation
4 weeks after the start of the initial stabilization period (baseline)
and after 1 week, and 3 and 6 months of treatment with either
spironolactone or placebo. At baseline, 3 and 6 months dogs
were evaluated by history, physical examination, indirect systolic
blood pressure measured by Doppler method, standard six-lead
ECG for 5 min, right lateral and dorsoventral thoracic radiogra-
phy and echocardiography. Plasma sodium, potassium, urea,
creatinine and alanine aminotransferase (ALT) were measured.
At the 1-week visit, a history and physical examination were
Table 1. Scandinavian modified New York Heart Association (NYHA)
system for classification heart failure stage in dogs with mitral valve
disease
NYHA class Clinical findings
I Asymptomatic dogs with murmurs but no
cardiac enlargement.
II Asymptomatic dogs with murmurs and
cardiac enlargement but no pulmonary
oedema or congestion.
III Slightly or moderately symptomatic dogs
(dyspnoea, increased heart rate and
disappearance of sinus arrhythmia) with
murmurs, cardiac enlargement and
interstitial pulmonary oedema.
IV Severely symptomatic dogs with murmurs,
cardiac enlargement and alveolar
pulmonary oedema.
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performed and a blood sample was taken for measurement of
sodium, potassium, urea and creatinine. The clinical variables
were assessed using a scoring system widely used in veterinary
clinical cardiac trials (IMPROVE study, 1995; Smith et al., 2005;
Table 2). Additional historical parameters were the following:
presence or absence of syncope, vomiting, diarrhoea, polydipsia
and polyuria. Parameters assessed during physical examination
were body weight, colour of mucous membranes, capillary refill
time, presence of a jugular pulse or jugular distension, dyspnoea,
pulse rate and quality, the presence of a precordial thrill, rectal
temperature, heart rate, respiratory rate, murmur grade, inten-
sity, radiation and point of maximum intensity and respiratory
noises.
Indirect systolic blood pressure measurement was performed
using an ultrasonic Doppler flow detector (Parks Medical
Electronics, Aloha, OR, USA) with all dogs in lateral recumbence.
Either the metacarpal or metatarsal artery was used while the
paw was held at the level of the right atrium. Cuff size and
location used were recorded, and the same technique was
maintained for each individual dog for all consecutive visits.
A total of four measurements were performed. The first
measurement was discarded, and the mean systolic blood
pressure was calculated as a mean of the following three
measurements.
A standard 6-lead ECG (Spacelabs Burdick, Deerfield, WI, USA)
was performed with patients positioned in right lateral recum-
bency. The ECG trace was assessed for heart rate, waveforms,
intervals and the presence or absence of arrhythmias. Thoracic
radiographs were assessed for size of the cardiac silhouette,
chamber enlargements and signs of pulmonary congestion.
The size of the heart was measured using the vertebral heart
size (VHS), which is a number that normalizes heart size to body
size using mid-thoracic vertebrae as units of measure (Buchanan
& Bu¨cheler, 1995). Others have called this vertebral heart
system.
Haemodynamic evaluation
Two-dimensional, M-mode and Doppler echocardiography were
performed without sedation using a 7.5, 5.0 and 2.5 MHz
transducer (Esaote Megas, Pie Medical Equipment, Maastricht,
the Netherlands). Three measurements were made for each
variable, and the average value was used in the statistical
analysis. Simultaneous ECG was performed during the echocar-
diographic examination. Two-dimensional and M-mode vari-
ables were determined in accordance with the guidelines
established by the American Society of Echocardiography
(Schiller et al., 1989; O’Grady et al., 2005). All echocardio-
graphic parameters measured are listed in Table 5.
NT-proANP and aldosterone
At baseline, 3- and 6- month blood samples were collected in
iced 5- mL polyethylene tubes containing EDTA (25 lmol) and
aprotinin (Aprotinin, Trasylol; Bayer, Leverkusen, Germany) for
measurement of NT-proANP and in dry tubes for measurement
Table 2. Scoring system used for clinical variables evaluated in dogs with heart failure (Amended from The Improve Study Group, 1995)
Cough scores Respiratory effort Appetite
0 – None 0 – Normal 1 – Increased
1 – Occasional 1 – Mildly increased effort 2 – Normal
2 – Frequent 2 – Laboured 3 – Decreased
3 – Persistent 3 – Respiratory distress 4 – Markedly decreased
Mobility Attitude Activity
1 – Very good: walks well, runs, capable of
some strenuous activity.
1 – Increased: has stronger desire and
interest than in the past to go out for
walks or play with owner. Appears more
alert and responsive to surrounding
environment.
1 – High: moves around with ease, capable
of climbing stairs or running short
distances. Alert and responsive to
external stimuli.
2 – Good: walks well, will run a short
distance or pulls on lead but unable to do
strenuous activity, tires easily after
walking 1–2 blocks.
2 – Remained the same: has
approximately the same degree of interest
and desire to go out for walks or play
with the owner as in the past, is more alert to
the surrounding environment as before.
2 – Moderate: tends to be inactive but
moves around a few times per day. Has
difficulty with stairs and avoids long
walks.
3 – Moderate: will walk, but for a limited
distance before needing to rest.
3 – Decreased: has some interest, but plays
less often, and has decreased interest to
go for a run or walk.
3 – Low: generally inactive, tendency to
remain in one place most of the day and
is unable to climb stairs or walk more
than short distance.
4 – Poor: can only walk a few yards before
needing to rest.
4 – Minimal: remains inactive all day and
only gets up to eat, drink or urinate.
5 – Very poor: to get up and move is a
major effort, only able to move a few
steps before resting.
5 – Incapacitated: will only get up or move
if strongly encouraged by owner.
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of aldosterone. After centrifugation within 30 min (2000 · g,
10 min, 4C), serum and plasma samples were frozen at )20C
and run batch wise at the end of the trial using radioimmunoas-
says validated for use in canine plasma (Aldosterone RIA:
Coat-a-count TKAL 1,2; Diagnostic Products Corporation,
Los Angeles, CA, USA).1 All measurements were performed in
duplicate. For aldosterone, the antiserum used had a cross-
reactivity of 100% for aldosterone and of <0.03% for other
compounds. The lowest limit of detection was 30.5 pmol/l and
the coefficient of variation was 7.7%. For NT-proANP, the
antiserum used had a cross-reactivity of 100% for human NT
pro-ANP1-126 and NT-proANP 1-98 and a cross-reactivity of
<0.01% for other natriuretic peptides. The lowest limit of
detection was 0.03 fmol/l and the coefficient of variation in the
study was 5.5%.
Endpoints
Predefined endpoints were end of the trial, euthanasia, death or
discontinuation of the trial as a direct consequence of heart
failure and discontinuation of the trial for reasons other than
worsening of heart failure.
Statistical analysis
The survival curves of the two groups were determined by the
Kaplan–Meier method and were compared by the log-rank test
and the Cox proportional hazard model.
The results were expressed as mean ± standard deviation (SD)
for quantitative variables. Baseline characteristics of the two
treatment groups were compared to assess the level of balance
between the two groups: the Wilcoxon rank-sum test was used
to compare quantitative variables, while the chi-squared test was
used for qualitative variables. To study the evolution of the
echocardiographical and biochemical parameters over time,
generalized linear mixed models were used, including the
baseline overall clinical score as covariate to account for baseline
difference between the two groups. Calculations were always
carried out on the maximum number of data available. Missing
data were not replaced. Results were considered to be significant
at the 5% critical level (P < 0.05). Statistical analysis was
carried out using SAS (version 9.1 for Windows, SAS Institute
Inc., Cary, NC, USA) and S-Plus (version 9.0, TIBCO Software
Inc., Palo Alto, CA, USA) software packages.
Power calculation was performed after the end of the trial and
was based on the mean survival times observed in the study
(Lachin & Foulkes, 1986). Power calculation was not performed
pretrial because specific survival data needed to formulate a
reasonable assumption were not available and extrapolations




A total of 18 dogs were enrolled in the study between February
2003 and October 2004. Breeds represented were Bichon Frise
(n = 3), Labrador retriever (n = 2), mixed breeds (n = 3) and 1
each of the following: Miniature Poodle, Maltese terrier, Wire-
haired Dachshund, Miniature Pinscher, Rough Collie, German
Shepherd, Boxer, Newfoundland, Whippet and Rottweiler.
Baseline characteristics
Baseline characteristics of the dogs enrolled in the study are
presented in Table 3. At baseline, the overall clinical score was
significantly higher in the spironolactone group than in the
control group (7.1 ± 1.8 vs. 5.2 ± 1.6, P < 0.05), because of
higher mobility and activity scores. Atrial fibrillation was present
in three dogs from the spironolactone group but only 1 dog in
the control group. Mean serum potassium, while being within
the normal range in all dogs, was significantly higher in the
spironolactone group at baseline (4.4 ± 0.6 vs. 3.8 ± 0.3 mmol/l,
P < 0.05).
Progression of clinical and haemodynamic parameters, NT-proANP
and aldosterone
No adverse events were observed in the study population over the
study period of 6 months. Progression of clinical, haemodynamic,
biochemical and neurohumoral parameters in the two treatment
groups during the study is presented in Tables 4 and 5. No
significant difference was found between the two treatment
groups with regard to the clinical score. The overall clinical score
significantly increased in dogs with DCM but not in dogs with
DVD over time (P < 0.01). Mean heart failure class increased
over time in both treatment groups (P < 0.01). Dogs in the
control group had a higher risk of moving into a higher class of
heart failure than dogs in the spironolactone group (P < 0.05).
Mean NT-proANP concentration increased significantly over
time in the spironolactone group and significantly decreased in
the control group (P < 0.0001). Plasma aldosterone concentra-
tions ranged between 0 and 461 pmol/l (mean 135 ± 106 pmol/l).
There was no significant difference between groups and no
significant changes over time; however, only a small number of
samples was available for assessment at 6 months.
Outcome – endpoints
There was no significant difference between the two treatment
groups regarding survival (Fig. 1). The survival probability decreased
with increasing doses of furosemide (P < 0.05). There was no effect
of pimobendan on the survival probability (P > 0.05).
1NT-proANP •Biotop (Medipolis center, Kivihartjuntie 11, Fin-90220
OULU – Finland), code BT02-100 tubes. The antibody employed in this
kit is directed to the amino acid residues 80–96 of the human ANP
sequence, which is identical to that observed in canine and feline
NT-proANP over that region.
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Power calculation
The results of the power calculation are shown in Fig. 2. The
statistical power of the study was 80% to identify a difference by
85% between the hazards in the treated and the placebo groups
over a 24-month follow-up period.
To identify a survival difference of 70% between control and
treatment groups with an 80% statistical power over a
24-month period, a minimum of 33 dogs per group would be
needed. With a survival difference between groups of 20%, 190
dogs per group would need to be included to show a significant
difference over a 24-month period.
Table 3. Baseline characteristics of the 18 dogs included in the study. Results are reported for the entire population (n = 18) and according to the
treatment group (spironolactone ⁄ placebo)
Characteristics Total n = 18 Spironolactone n = 9 Placebo n = 9 P
Age (years) 9.6 ± 2.2 9.7 ± 1.7 9.6 ± 2.7 0.89
Sex
Male (all entire) 11 7 4 0.15
Female (entire ⁄ neutered) 7 2 (1 ⁄ 1) 5 (2 ⁄ 3)
Body weight (kg) 23.2 ± 18.4 29.7 ± 20.9 16.7 ± 13.7 0.17
Pathology
DVD 11 6 5 0.63
DCM 7 3 4
Clinical score
Cough 0.6 ± 0.6 0.7 ± 0.7 0.4 ± 0.5 0.52
Dyspnoea 0.3 ± 0.5 0.2 ± 0.4 0.4 ± 0.5 0.35
Appetite 2.1 ± 0.5 2.1 ± 0.8 2.0 ± 0.0 0.99
Attitude 1.9 ± 0.6 2.0 ± 0.7 1.8 ± 0.4 0.46
Mobility* 1.8 ± 0.7 2.2 ± 0.7 1.4 ± 0.5 0.021
Activity* 1.5 ± 0.6 1.9 ± 0.6 1.1 ± 0.3 0.01
Overall score* 6.2 ± 2.0 7.1 ± 1.8 5.2 ± 1.6 0.047
Syncope 1 1 1 0.99
Vomiting ⁄ diarrhoea 4 1 3 0.26
PU ⁄ PD 13 6 7 0.60
Clinical parameters
Increased respiratory effort 0.22 ± 0.44 0.33 ± 0.50 0.28 ± 0.46 0.62
Respiratory rate (breaths ⁄min) 30.4 ± 24.8 24.6 ± 20.4 36.3 ± 28.5 0.37
Heart rate (beats ⁄min) 133.2 ± 27.5 139.8 ± 30.7 126.7 ± 23.8 0.23
Heart failure stage
II 12 5 7 0.23
III 6 4 2
IV – –
Systolic blood pressure (mmHg) 138 ± 33 152 ± 36 121 ± 20 0.10
VHS 11.8 ± 1.2 11.3 ± 0.8 12.3 ± 1.3 0.11
Serum biochemistry
Urea (mg ⁄ dL) 24.6 ± 10.7 22.9 ± 5.8 26.5 ± 14.7 0.96
Creatinine (mg ⁄ dL) 1.35 ± 0.38 1.33 ± 0.44 1.36 ± 0.34 0.50
ALT (U ⁄ L) 92.8 ± 95.6 75.7 ± 54.7 112 ± 129 0.70
Sodium (mmol/l) 147.4 ± 3.7 147.1 ± 3.7 147.6 ± 4.0 0.99
Potassium (mmol/l)* 4.1 ± 0.6 4.4 ± 0.6 3.8 ± 0.3 0.042
Neuroendocrine parameters
NT-proANP (fmol/l) 0.81 ± 0.46 0.70 ± 0.41 0.95 ± 0.51 0.63
Aldosterone (pmol/l) 139 ± 116 147 ± 144 129 ± 76 0.63
Number of dogs receiving medication
Furosemide (n) 17 8 9 0.30
Mean Furosemide dose (mgÆkg ⁄ day) 4.2 ± 2.1 4.0 ± 1.7 4.4 ± 2.4 0.85
ACE inhibitor
Benazepril (n) 15 8 7 0.53
Enalapril (n) 3 1 2 0.53
Pimobendan§ (n) 9 4 5 0.64
Digoxin– (n) 2 1 1 0.99
Significantly different results are indicated with an asterisk (*); Furosemide EG; Eurogenerics, Omega Pharma, Brussels, Belgium; Fortecor; Novartis
Animal Health, Brussels, Belgium; Enacard; Merial, Anderlecht, Belgium; §Vetmedin; Boehringer Vetmedica GmbH, Ingelheim, Germany; –Lanoxin;
GlaxoSmithKline, Genval, Belgium; DVD, degenerative valve disease; DCM, dilated cardiomyopathy; PU ⁄ PD, polyuria and polydipsia; VHS, vertebral heart
size; ALT, alanine aminotransferase; NT-proANP, aminoterminal atrial natriuretic propeptide; ACE inhibitor, angiotensin-converting enzyme inhibitor.
326 S. Schuller et al.
 2010 Blackwell Publishing Ltd
Table 4. Progression of clinical, biochemical, neurohumoral markers over the 6- month study period in the two treatment groups
Parameter Group n Baseline n 3 months n 6 months
Clinical score
Cough S 9 0.7 ± 0.7 7 0.7 ± 0.8 6 0.7 ± 0.5
P 9 0.4 ± 0.5 7 0.7 ± 0.8 5 1.0 ± 1.4
Dyspnoea S 9 0.2 ± 0.4 7 0.1 ± 0.4 6 0 ± 0
P 9 0.3 ± 0.5 7 0.3 ± 0.5 6 1.2 ± 1.2
Appetite(a) S 9 2.1 ± 0.8 7 2.1 ± 0.7 5 2.2 ± 0.5
P 9 2.0 ± 0.0 7 1.9 ± 0.7 5 2.8 ± 1.1
Attitude(a) S 9 2.0 ± 0.7 7 1.6 ± 0.5 6 2.0 ± 0.6
P 9 1.8 ± 0.4 7 2.0 ± 0.6 4 1.8 ± 1.0
Mobility S 9 2.2 ± 0.7 7 2.1 ± 0.4 6 2.0 ± 0.6
P 9 1.4 ± 0.5 7 1.6 ± 0.5 4 2.3 ± 1.3
Activity S 9 1.9 ± 0.6 7 1.6 ± 0.5 6 1.8 ± 0.8
P 9 1.1 ± 0.3 7 1.1 ± 0.4 4 1.5 ± 1.0
Overall score(a) S 9 7.1 ± 1.8 7 7.0 ± 1.2 6 6.5 ± 2.4
P 9 5.2 ± 1.6 7 5.6 ± 1.5 6 6.8 ± 2.9
Other clinical findings
Syncope S 9 1 6 0 6 0
P 9 1 7 0 6 0
Vomiting ⁄ diarrhoea S 9 1 7 1 6 0
P 9 3 7 2 6 1
PU ⁄ PD S 9 6 7 6 6 6
P 9 7 7 6 6 5
Increased respiratory effort S 9 0.2 ± 0.4 7 0.1 ± 0.6 6 0.0 ± 0.0
P 9 0.3 ± 0.5 7 0.3 ± 0.5 6 1.2 ± 1.2
Respiratory rate S 9 24.6 ± 20.4 7 18.4 ± 18.2 6 6.2 ± 12.7
P 9 36.3 ± 28.5 6 22.8 ± 26.7 5 51.0 ± 40.3
Heart rate S 9 140 ± 30.7 7 116 ± 24.5 6 119 ± 11.7
P 9 127 ± 238 7 122 ± 24.8 6 130 ± 301
Electrocardiogram heart rate(a) S 7 134 ± 22.2 6 128 ± 26.4 5 120 ± 7.1
P 9 146 ± 27.4 7 143.4 ± 38.9 5 131 ± 26.0
Heart failure stage(a),(b)
II S 5 ⁄ 9 3 ⁄ 6 3 ⁄ 5
III S 4 ⁄ 9 2 ⁄ 6 2 ⁄ 5
IV S 0 ⁄ 9 1 ⁄ 6 0 ⁄ 5
II P 7 ⁄ 9 5 ⁄ 6 1 ⁄ 5
III P 2 ⁄ 9 1 ⁄ 6 3 ⁄ 3
IV P 0 ⁄ 9 0 ⁄ 6 2 ⁄ 3
Blood pressure S 8 152 ± 36 6 148 ± 29 4 141 ± 15
P 7 121 ± 19 4 122 ± 36 4 151 ± 32
VHS S 8 11.3 ± 0.8 6 12.0 ± 0.8 5 11.6 ± 0.8
P 8 12.3 ± 1.3 6 12.2 ± 0.9 6 12.3 ± 1.4
Plasma biochemistry
Urea (mg ⁄ dL) S 9 22.9 ± 5.8 7 24.9 ± 7.8 5 29.6 ± 14.1
P 8 26.5 ± 14.7 6 30.0 ± 5.2 3 30.0 ± 17.7
Creatinine (mg ⁄ dL) S 9 1.33 ± 0.44 7 1.29 ± 0.32 6 1.37 ± 0.29
P 8 1.36 ± 0.34 6 1.38 ± 0.26 3 1.03 ± 0.49
ALT (U ⁄ L) S 9 75.7 ± 54.7 7 98.3 ± 134 2 35.5 ± 0.7
P 8 112 ± 129 6 93.5 ± 112 2 34.5 ± 20.5
Sodium (mmol/l) S 9 147 ± 3.7 7 150 ± 5.0 5 142 ± 3.9
P 8 148 ± 4.0 6 145 ± 4.4 3 147 ± 7.1
Potassium (mmol/l) S 9 4.4 ± 0.6 7 4.1 ± 0.5 6 3.9 ± 0.5
P 8 3.8 ± 0.3 6 3.7 ± 0.4 3 4.2 ± 0.5
Neuroendocrine markers
NT-proANP (fmol/l)(a),(b) S 9 0.70 ± 0.41 7 0.83 ± 0.55 5 0.83 ± 0.44
P 7 0.95 ± 0.51 6 0.47 ± 0.46 2 0.32 ± 0.29
Aldosterone (pmol/l) S 9 147 ± 144 7 96.5 ± 62.3 2 104 ± 32.2
P 7 129 ± 76.3 5 172 ± 144 1 216
Parameters with significant time evolution are indicated with (a), parameters showing significantly different evolution between the two treatment
groups are indicated with (b); Heart Failure Stage according to Scandinavian modified New York Heart Association System for heart failure classification
in dogs with mitral valve disease (Table 1); S, spironolactone; P, placebo; PU ⁄ PD, polyuria and polydipsia; VHS, vertebral heart size; ALT, alanine
aminotransferase; NT-proANP, aminoterminal atrial natriuretic propeptide.
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DISCUSSION
The aim of this randomized prospective double-blinded placebo-
controlled clinical study was to assess the efficacy and tolerance
of spironolactone when added at a low dose to conventional
heart failure treatment in dogs with advanced heart failure due
to either DVD or DCM.
The results of this study show that addition of spironolactone
at a dose between 0.49 and 0.8 mg ⁄ kg per day to conventional
heart failure treatment was not associated with any adverse
events. In particular, there was no measurable effect on plasma
potassium concentrations. This finding is of importance, given
reports of life-threatening hyperkalaemia in human patients
treated with a combination of ACE inhibitors and spironolactone
(Berry & McMurray, 2001; Juurlink et al., 2004). The present
results are in accordance with the findings of Thomason et al.
(2007) and Bernay et al. (2010), who reported no significant
difference in serum potassium in dogs with DVD treated with a
combination of ACE inhibitors and spironolactone at a mean
dose of 1.49 ± 0.54 mg ⁄ kg twice daily and 2.33 ± 0.34 mg ⁄ kg
once daily, respectively.
In this present study, no significant effect of spironolactone on
survival could be shown. Dogs in the control group had a higher
risk of moving into a higher heart failure stage than dogs in the
spironolactone group during the 6 months of the trial. This
might indicate a potential beneficial effect of spironolactone on
the progression of heart failure, but this finding was not
supported by other parameters evaluated in this study such as
clinical score, ECG abnormalities, blood pressure, VHS and
haemodynamic parameters.
Table 5. Haemodynamic parameters over the
6- month study period in the two treatment
groups
Parameter Group n Baseline n 3 months n 6 months
IVSd (mm) S 8 8.7 ± 2.9 7 9.1 ± 3.5 5 11.3 ± 3.7
P 9 8.9 ± 2.9 7 8.5 ± 4.0 6 6.8 ± 2.3
IVSs (mm) S 8 13.8 ± 3.5 7 13.8 ± 4.5 5 14.4 ± 5.1
P 9 12.3 ± 3.0 7 12.6 ± 3.6 6 12.7 ± 1.9
LVd (mm) S 8 52.3 ± 20.1 7 49.1 ± 19.6 5 47.1 ± 19.5
P 9 49.3 ± 17.2 7 48.9 ± 18.6 6 52.5 ± 21.0
LVs (mm) S 8 35.8 ± 17.4 7 31.8 ± 16.5 5 34.1 ± 17.1
P 9 36.0 ± 20.7 7 35.8 ± 22.2 6 35.6 ± 24.2
PWd (mm) S 8 9.1 ± 2.7 7 10.7 ± 5.2 5 10.2 ± 3.1
P 9 8.1 ± 2.0 7 8.4 ± 2.6 6 7.6 ± 1.9
PWs (mm) S 8 13.4 ± 3.6 7 14.8 ± 4.8 5 14.9 ± 4.2
P 9 10.6 ± 2.1 7 9.3 ± 5.1 6 12.3 ± 2.9
FS (%) S 8 37.1 ± 12.9 7 37.9 ± 11.9 5 29.0 ± 13.4
P 9 31.3 ± 16.2 7 31.7 ± 19.6 6 34.0 ± 15.9
EPSS (mm) S 8 6.7 ± 6.4 7 6.2 ± 6.0 4 3.6 ± 2.7
P 8 6.7 ± 7.3 7 2.1 ± 1.6 4 5.9 ± 8.1
LA2D (mm) S 7 40.9 ± 24.9 6 48.4 ± 23.6 5 41.6 ± 24.1
P 9 43.8 ± 10.3 5 50.3 ± 3.8 3 49.5 ± 11.7
Ao ⁄ LA S 7 1.65 ± 0.84 6 2.00 ± 0.83 5 2.19 ± 0.50
P 6 2.37 ± 0.90 5 2.51 ± 0.47 2 1.70 ± 1.13
Ao (m ⁄ s)(a) S 6 0.81 ± 0.37 6 1.09 ± 0.31 5 1.04 ± 0.43
P 9 1.34 ± 0.62 6 1.04 ± 0.21 4 1.19 ± 0.10
PA (m ⁄ s) S 8 0.66 ± 0.09 7 0.68 ± 0.22 5 0.67 ± 0.17
P 8 0.68 ± 0.18 7 0.69 ± 0.28 2 0.94 ± 0.12
PEP (ms) S 6 65.5 ± 17.9 6 55.8 ± 25.5 5 55.7 ± 17.9
P 8 68.9 ± 23.9 5 58.2 ± 12.5 3 60.7 ± 31.0
ET (ms) S 6 155 ± 17.4 6 156 ± 26.8 5 156 ± 29.6
P 8 162 ± 29.8 5 149 ± 32.3 3 148 ± 32.9
PEP ⁄ ET S 6 0.43 ± 0.14 6 0.38 ± 0.21 5 0.37 ± 0.12
P 8 0.44 ± 0.18 5 0.41 ± 0.14 3 0.39 ± 0.18
MV E ⁄A S 4 2.45 ± 1.17 3 2.33 ± 0.67 3 1.30 ± 0.26
P 6 2.28 ± 1.35 6 1.72 ± 0.54 3 1.68 ± 0.57
EVedt (m ⁄ s) S 5 45.3 ± 20.6 3 36.2 ± 5.5 3 31.0 ± 7.2
P 6 47.9 ± 34.0 5 40.4 ± 17.8 0 )
(a)Significant time evolution; IVSd, interventricular septum in diastole; IVSs, interventricular septum
in systole; LVd, left ventricular diameter in diastole; LVs, left ventricular diameter in systole; PWd,
posterior wall in diastole; PWs, posterior wall in systole; FS, fractional shortening; EPSS, mitral
E-point septal separation; LA 2D, left atrial size before the opening of the mitral valve in the right
parasternal long-axis view; Ao ⁄ LA, internal aortic diameter (Ao) and left atrial diameter from the
right parasternal short-axis view; Ao, maximal aortic outflow velocity; PA, maximal pulmonic
outflow velocity; PEP, pre-ejection period; ET, ejection time; MV E ⁄A, mitral inflow E ⁄ A ratio; MV
Edt, mitral inflow deceleration time of the E-wave.
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The findings of the present study differ from human data from
the RALES (Pitt et al., 1999) and the study performed by Bernay
et al. (2010) in a population of dogs with moderate to severe
mitral valve disease. In the latter study, which was a
prospective, placebo-controlled field trial including 212 dogs, a
69% reduction in risk of cardiac death or euthanasia was
reported for the spironolactone group.
The exact mechanism of the potential beneficial effects of
spironolactone in patients with heart failure is uncertain and
may be multifactorial. There is strong evidence from humans
and various animal heart failure models that mineralocorticoid
receptor antagonists, such as spironolactone, reduce excessive
extracellular matrix turnover and myocardial remodelling, thus
slowing down progression of heart disease (Rousseau et al.,
2002; Suzuki et al., 2002; Hayashi et al., 2003; Karram et al.,
2005). Study of a subgroup of the RALES patient population
showed a significant decrease in BNP and NT-proANP associated
with an increase in angiotensin II and aldosterone in patients
treated with low-dose spironolactone, indicating effective aldo-
sterone receptor blockade (Rousseau et al., 2002). These findings
provide further evidence for a potential neuroendocrine modu-
lation as mechanism of action for the beneficial effects of
spironolactone in heart failure patients (Rousseau et al., 2002).
The lack of a measurable beneficial effect of spironolactone in
this population of dogs could be a result of several factors
including a small patient population, insufficient treatment dose
and differences in baseline characteristics between spironolac-
tone and control group.
The small patient number is a major limitation of this study.
Power calculation performed after completion of the study
showed that the number of dogs included was insufficient to
conclusively demonstrate or disprove a survival benefit. Based on
this data, up to 200 dogs per treatment group may be required to
be able to show a significant difference between treatment
groups. Such large patient numbers can only be completed in
reasonable time using a multicentre approach, which have their
own limitations, such as increased interobserver variability.
The low dose of spironolactone used may be another possible
explanation for the lack of a detectable clinical effect of
spironolactone in this study. This study was modelled after the
RALES trial in which a low dose of 25 mg ⁄ person was used in an
effort to avoid diuresis (Pitt et al., 1999). We aimed at using a
dose, which would be clearly below the approved diuretic dose in
dogs (2–4 mg ⁄ kg once daily), to be able to show that potential
positive effects of spironolactone are in fact due to other than
diuretic effects. Specific pharmacological data from dogs were not
available at the time of the study, thus the dose of 0.49–
0.8 mg ⁄ kg once daily was chosen. In the meantime, data from a
canine hyperaldosterone model, which was specifically designed
to determine an effective dose of spironolactone for the mana-
gement of congestive heart failure in dogs, has been published.
In this experimental model a spironolactone dose of
1.08 ± 0.28 mg ⁄ kg only inhibited aldosterone actions by 50%.
(Guyonnet et al., 2009). Based on these results, it is likely that
the dose used in the present trial was too low to provide sufficient
aldosterone receptor blockade. This hypothesis is supported by
the fact that plasma aldosterone did not increase in dogs in the
spironolactone group during treatment which is in contrast to
humans in the RALES study in which plasma aldosterone
concentrations increased during treatment indicating activated
feedback mechanisms (Rousseau et al., 2002). A lack of effective
aldosterone receptor blockage could explain the differences in
outcome between the present study and the study of Bernay et al.
(2010), in which a mean daily dose of spironolactone of
2.33 ± 0.34 mg/kg was used. Based on these findings, the use
of a dose of 2 mg ⁄ kg once daily is advocated for further trials and
active metabolites of spironolactone as well as plasma aldoste-






























Fig. 1. Kaplan–Meier Curve showing lack of survival benefit in dogs with
advanced degenerative valve disease or dilated cardiomyopathy treated




















Difference between hazard rates (%)
Fig. 2. Power calculation showing the minimum number of dogs per
group needed to show a difference with an 80% statistical power over a
24- month period between the treatment and control groups. The hazard
rate is the number of instantaneous deaths. According to the calculation,
a minimum of 33 dogs per group are needed to show a significant
difference between groups with a survival difference between groups
of 70%.
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receptor blockade as well as owner compliance. These findings
also emphasize the importance of dose-finding trials ahead of the
study of specific clinical outcomes in relation to drug therapy.
There were some differences between the two treatment
groups at baseline, which could account for the lack of
measurable beneficial effect of spironolactone. Three dogs in
the spironolactone group but only one dog in the control group
showed atrial fibrillation, which may suggest more advanced
disease and a potentially poorer prognosis in the dogs in this
group (Calvert et al., 1997). Secondly, there was a higher overall
clinical score in the spironolactone group at baseline. When this
difference was detected, the clinical score was introduced as a
covariant into the statistical model to exclude bias because of
existing baseline differences. However, even after adjustment for
the difference in the baseline clinical scores, no significant effect
of spironolactone could be found. On the other hand, dogs with
DCM and DVD were equally distributed between the two
treatment groups and the mean daily dose of furosemide, which
can be used as an indicator of severity of cardiac disease, was not
significantly different between treatment groups (Smith et al.,
2005).
Other findings of this study were, firstly, that dogs with DVD
were significantly more likely to be presenting cough, which
could be secondary to a relatively larger left atrial size because of
more marked mitral regurgitation, leading to compression of the
left mainstem bronchus. Secondly, it was found that the total
daily dose of furosemide was inversely correlated with survival,
which underlines the value of this parameter as a marker of
severity of heart failure (Smith et al., 2005). The results of this
study showed no effect of pimobendan on survival; however, this
was not an endpoint of the study.
Plasma aldosterone and NT-proANP were assessed as neuro-
endocrine markers of heart failure. The results have to be
interpreted with caution given that only a limited number of
samples could be assessed, especially at 6 months. Plasma
aldosterone was unaffected by spironolactone treatment. NT-
proANP increased significantly over time in the spironolactone
group and significantly decreased in the control group. This
finding was unexpected. Human patients with hyperaldostero-
nism typically show high plasma ANP concentrations, which
acts to counterbalance the aldosterone-induced sodium and
water retention (Levin et al., 1998). Therefore, with aldosterone
receptor blockade via spironolactone, a decrease rather than an
increase in NT-proANP had been expected. However, increases
in NT-proANP may explain the lack of a survival benefit in the
spironolactone group. NT-proANP has been associated with
substantially decreased survival times in humans with conges-
tive heart failure (Dickstein et al., 1998). It was highly
correlated with heart rate, echocardiographic dimensions of
the left atrium and left ventricle and fractional shortening in
dogs with DCM as well as enlargement of the left atrium and
ventricle in dogs with chronic valvular disease and could
therefore indicate that dogs in the spironolactone group had
potentially more advanced heart disease (Ha¨ggstro¨m et al.,
1994; Tidholm et al., 2001).
This study is of relevance for future trials. Firstly, the study
design proved to be feasible in the setting of a busy teaching
hospital. Secondly, power calculation indicated that at least 66
patients need to be included in the study to be able to show
significant survival differences between treatment groups assum-
ing a reduction in survival of 69%, as described by Bernay et al.,
2010. Therefore, a multicentre approach should be applied.
Thirdly, a higher dose of spironolactone should be used, and
active metabolites in plasma should be monitored to prove that
an effective dose is used and to verify owner compliance.
CONCLUSIONS
In conclusion, it can be stated that addition of spironolactone at
a low dose to conventional heart failure treatment (furosemide,
ACE inhibitor, pimobendan, digoxin) in dogs with acquired
heart disease is well tolerated. It may improve heart failure class
but beneficial effects on survival could not be shown in this
study.
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